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Abstract 
 
Diabetes mellitus is a disease characterized by chronic hyperglycemia either due to a lack 
of secretion of the hormone insulin (Type 1 Diabetes Mellitus, T1DM) or due to impaired 
action of this hormone (Type 2 Diabetes Mellitus, T2DM). Due to its short- and long-term 
complications,  it  is  currently  one  of  the  major  health  problems  of  the  economically 
developed countries and at the same time, one of the first items of healthcare spending. 
Diabetic patients therefore need regular blood glucose monitoring associated with adequate 
insulin therapy whose goal is to keep glucose concentration within the normal safe range 
(70  180 mg/dl), trying to limit excursions in hypoglycemic (20  70 mg/dl), due to short-
term  complications,  and  hyperglycemic  range  (180    600  mg/dl),  due  to  long-term 
complications. In order to optimize insulin therapy, and then assess the correct amount of 
insulin to be administered to the patient, it is necessary to know its insulin sensitivity (SI), 
i.e. the ability of insulin to stimulate glucose utilization and inhibit its production, specific 
for each individual and changing during the day.   
The aim of this thesis is to estimate an index of insulin sensitivity in patients with type 
1diabetes  by  using  a  recently  proposed  technique  which  exploits  minimally  invasive 
technologies used by diabetic patients for control therapy. This parameter will be estimated 
in correspondence of meals over the whole day and, in order to be able to estimate the 
index of insulin sensitivity even in the presence of meals close, a tool for the estimation of 
carbohydrates  absorbed  during  the  meal  (Carbohydrates  On  Board,  COB)  will  be 
proposed.   
In  Chapter  1  the  glucose-insulin  regulatory  system,  diabetes  and  its  complications, 
conventional  therapy  for  its  control  and  indices  of  insulin  sensitivity  in  literature  are 
introduced. 
In Chapter 2 the experimental protocols applied to the patients and the data available data 
are presented.  
In  Chapter  3  the  recently  proposed  method  for  the  estimation  of  SI  using  minimally 
invasive technologies and the COB function for the estimation of carbohydrates absorbed 
during the meal are presented.   iv 
 
In Chapter 4 the estimates of insulin sensitivity in different datasets with and without the 
COB function, which in turn was developed using simulated and real data, are presented. 
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1. Introduction 
 
1.1. The glucose-insulin regulatory system 
 
The  study  of  glucose  metabolism  is  fundamental  both  from  a  physiological,  because 
glucose is the main source of energy for the whole body cells, and from a pathological 
point of view, because a malfunction of this system would lead to phenomena of glucose 
intolerance or, in the worst case, to diabetes. 
The concentration of glucose in healthy subjects is tightly regulated by a complex neuro-
hormonal control system. Insulin, which is secreted by the -cells of the pancreas, is the 
primary regulator of glucose homeostasis, by promoting its use by tissues and inhibiting its 
endogenous  production.  On  the  other  side,  hormones  such  as  glucagon,  epinephrine, 
cortisol,  and  growth  hormone  play  the  role,  on  different  time  scales,  to  prevent 
hypoglycemia. 
Glucose is generally absorbed by the gastro-intestinal tract through food digestion after a 
meal or, in fasting condition, it is provided primarily by the liver. It is distributed and used 
in the whole body and, based on the specific needs and roles in  its regulation, we can 
classify tissues and organs (Fig. 1.1): 
 
 
Figure 1.1 The glucose-insulin control system, [1]. 
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  Insulin-independent:  central  nervous  system  and  erythrocytes.  Glucose  is  the 
substrate of choice and its extraction takes place at a constant speed, regardless of 
insulin concentration. 
  Insulin-dependent: muscle, adipose tissue and liver. The utilization of glucose by 
these tissues is phasic; in fact it is modulated by the amount of circulating insulin. 
  Gluco-sensors:  pancreas  -cells,  liver  and  hypothalamus.  They  are  sensitive  to 
glucose concentration and they could provide a proper secretory response. 
 
In Fig. 1.1 is showed a schematic representation of the glucose-insulin control system. In 
the upper part we can find the production of glucose, mainly provided by the liver and its 
utilization, mediated and not by insulin action. In the lower part we can find the secretion 
of  insulin  from of the -cells and  its degradation  by tissues. Dashed arrows show the 
mutual control between glucose and insulin, where insulin promotes glucose utilization and 
inhibits its production, while glucose stimulates insulin secretion.  
It is therefore evident that a well-regulated control system is in closed loop form (Fig. 1.2): 
glucose  stimulates  insulin  secretion  and  this,  in  turn,  acts  on  glucose  production  and 
utilization. 
 
 
Figure 1.2: Glucose-insulin control system in closed loop, [2]. 
 
An imbalance of this feedback control system can lead to diseases such as diabetes. 
    
 
1.2. Diabetes 
 
Diabetes  is  a  chronic  disease  characterized  by  either  an  autoimmune  destruction  of 
pancreas -cells, leading to insulin deficiency (Type 1 Diabetes Mellitus, T1DM), or by 
insulin  resistance  (Type  2  Diabetes  Mellitus,  T2DM)  which  may  be  combined  with 
impaired  insulin secretion.  As a result, in diabetic subjects the plasma glycaemic  level 
exceeds the normal range, with several long- and short-term complications. It is expected 
that  by  the  year  2030  there  may  be  close  to  400  million  people  with  diabetes.  It  is 
important to note the fact that at least 50% of the entire diabetic population is unaware of 
its condition and in many countries this data reaches 80%. Every year 3.8 million deaths 
are caused by complications due to diabetes and, in fact, it is considered currently the 
fourth leading cause of death worldwide. 
 
1.2.1. Type 1 diabetes 
 
Type 1 diabetes is the form of diabetes which results from autoimmune destruction of 
insulin-producing -cells of the pancreas (Fig. 1.3). The insulin deficiency results in the 
inability of cells (in particular fat and muscle) to utilize and store glucose, with immediate 
consequences: 
  Accumulation of glucose in plasma which leads to strong hyperglycemia, to exceed 
the threshold of renal reabsorption causing glycosuria, polyuria and polydipsia. 
  Use of alternative sources of energy such as the lipid reserves, bringing the loss of 
body fat and protein reserves with loss of lean body mass. 
Type 1 diabetes is less than 10% of cases of diabetes and it  is a disease of childhood thus 
affecting mostly children and adolescents, more rarely young adults (90% <20 years). 
   6 
 
1.2.2. Type 2 diabetes 
 
Type 2 diabetes  is characterized  by three physiological abnormalities:  impaired  insulin 
secretion, insulin resistance and overproduction of endogenous glucose. 
It is the most common type of diabetes (more than 90% of cases) and it is a typically 
disease of mature age (> 40 years), even if it starts to affect patients getting younger. The 
pathogenesis of type 2 diabetes is caused by a combination of lifestyle (obesity, lack of 
physical  activity,  etc.)  and  genetic  factors.  This  form  of  diabetes  frequently  goes 
undiagnosed for many years because the hyperglycemia develops gradually and at earlier 
stages it is often not severe enough for the patient to notice any of the classic symptoms of 
diabetes. Whereas patients with this form of diabetes may have insulin levels that appear 
normal or elevated, the higher blood glucose levels would be expected to result in even 
higher insulin values it they had their β-cell function been normal. Thus, insulin secretion 
is defective in these patients and insufficient to compensate glucose levels due to insulin 
resistance. Insulin resistance may improve with weight reduction and/or pharmacological 
treatment of hyperglycemia but is seldom restored to normal [3]. 
 
1.2.3. Complications 
 
All  forms  of  diabetes  increase  the  risk  of  long-term  complications,  which  are  mainly 
related to damage to blood vessels:  in  fact diabetes doubles the risk of cardiovascular 
disease  [4, 5].  The  main  "macrovascular"  diseases  (related  to  atherosclerosis  of  larger 
arteries)  are  ischemic  heart  disease  (angina  and  myocardial  infarction),  stroke  and 
peripheral vascular disease; while the main "microvascular" complications (damage to the 
small blood vessels) are: 
  Diabetic retinopathy: (70% T1DM, 40% T2DM) it affects blood vessel formation 
in the retina of the eye, leading to visual symptoms, reduced vision, and potentially 
blindness. 
  Diabetic nephropathy: (20-30% of diabetic patients) the impact of diabetes on the 
kidneys  can  lead  to  scarring  changes  in  the  kidney  tissue,  loss  of  small  or  
 
progressively larger amounts of protein in the urine, and eventually chronic kidney 
disease requiring dialysis. 
  Diabetic neuropathy: (20-40% of diabetic patients) it is the impact of diabetes on 
the nervous system, most commonly causing numbness, tingling and pain in the 
feet and also increasing the risk of skin damage due to altered sensation. Together 
with vascular disease in the legs, neuropathy contributes to the risk of diabetes-
related foot problems (such as diabetic foot ulcers) that can be difficult to treat and 
occasionally require amputation. 
Equally  important  are  the  short-term  complications,  conditions  caused  by  either 
hypoglycemia or hyperglycemia. The first case occurs in people with diabetes treated with 
insulin or hypoglycemic agents and is more common in people who miss or delay meals 
after an insulin bolus or do physical activity unexpectedly, causing an increase in glucose 
utilization by tissues. In the second case [6] occurs diabetic ketoacidosis, usually in young 
people with type 1 diabetes, and the main cause is the absolute or relative deficiency of 
insulin.  Among  the  risks  are  cerebral  edema,  hyperchloremic  acidosis,  lactic  acidosis, 
infections,  gastric  dilation,  erosion  and  thromboembolism.  Another  complication  that 
affects,  however,  subjects  with  type  2  diabetes  is  the  hyperglycemic-hyperosmolar 
syndrome (mortality 10-60%) characterized by hyperosmolarity (plasma osmolality > 320 
mosm / kg), severe hyperglycemia (blood glucose > 600 mg / dl), marked dehydration, the 
absence of acidosis [7]. 
 
1.3 Control of Diabetes 
 
For  decades,  the  evaluation  of  the  patient's  glycemic  control  was  based  solely  on 
glycosuria  [8]  then,  with  the  introduction  of  self-home  capillary  blood  glucose,  ,  a 
fundamental level of quality was reached [9]. At the end of the 70s integrated indexes such 
as HbA1c [10] and glycated proteins [11] have been joined, but, till now, the self-blood 
glucose measurement (Self-Monitoring Blood Glucose, SMBG) remained an indispensable 
element,  enabling  enormous  progress,  both  in  clinical  terms,  making  possible  to  pass 
towards a real self-care [12, 13], and in terms of knowledge, documenting a number of 
aspects of the physiology and pathophysiology of glucose homeostasis [14, 15] that were 
previously only intuited.  8 
 
However,  because  of  the  wide  and  rapid  variations  in  blood  glucose  due  to  physical 
activity, diet, and pharmacological therapy, SMBG values are not sufficient to identify 
episodes of post-prandial hyperglycemia and especially those of hypoglycemia caused by 
an overdose of insulin.    
Since 2000  it  has  been possible to use techniques  for continuous  monitoring of  blood 
glucose throughout the day, trying to limit the invasiveness (minimally invasive or non-
invasive). In particular, systems have been proposed for continuous glucose monitoring 
(Continuous  Glucose  Monitoring,  CGM),  which  have  the  advantage  of  being  able  to 
provide almost continuous glucose measurement, essential to recognize critical events in 
real time. 
The standard treatment for patients with diabetes, especially for T1DM, is therefore based 
on multiple daily injections of insulin (bolus and basal doses), diet and exercise, tuned 
according  to  self-monitoring  of  blood  glucose  (SMBG)  levels  3  to  4 times  a  day,  but 
thanks to the availability of CGM sensors and insulin delivery systems has been possible to 
improve the management of diabetes. The SMBG however is still remained fundamental 
for  control  therapy  due  to  possible  systematic  and  random  errors  of  CGM  sensors, 
becoming of considerable importance the calibration procedure enabled by SMBG values. 
 
1.3.1. Continuous Glucose Monitoring Systems 
 
The difference between SMBG and CGM is evident: the amount of additional information 
that can be obtained from a tool that performs frequent measurements, without requiring 
the active intervention of the patient, even in times of the day which cannot be analyzed in 
detail with the traditional systems.  
This difference is exemplified in glycemic profile shown in Fig. 1.3: a trend apparently 
satisfactory, if judged by isolated points detected with SMBG, reveals significant glucose 
excursions when the observation is made in a "continuous" way. So SMBG provides a 
limited and isolated number of accurate measurements, thus only roughly indicative of the 
overall  picture,  instead  CGM,  if  correctly  calibrated,  gives  a  more  detailed  and 
representative picture of the real clinical situation. 
  
 
 
Figure 1.3: Comparison between a glycemic profile obtained with SMBG (filled circles) 
and CGM (continuous line). 
 
In the first continuous glucose monitoring system was offered only “offline” interpretation 
of the glucose profiles after disconnecting the sensor and uploading the results. In the past 
years,  “online”  or  “real-time”  continuous  glucose  monitoring  systems  have  become 
available, allowing direct feedback of glucose levels. 
CGM devices produced by Abbott, DexCom, and Medtronic have been approved by the 
U.S. Food and Drug Administration (FDA) and are available by prescription: these provide 
real-time measurements of glucose levels, with glucose levels displayed at 5-minute or 1-
minute intervals. Users can set alarms to alert them when glucose levels are too low or too 
high. Special software is available to download data from the devices to a computer for 
tracking and analysis of patterns and trends, and the systems can display trend graphs on 
the monitor screen [16]. 
As other biological parameters continuously monitored, glucose monitoring is based on the 
use of biosensors, i.e. of analytical devices equipped with a detection system, associated to 
a system of translation of signals. This mechanism allows to translate variations induced by 
chemical reactions or by physiological changes in digital electronic signals, the intensity of 
which is proportionate to the concentration of the analyte in the biological material under 
examination. 
  Conventionally, it is usual to distinguish continuous glucose monitoring devices in: 
totally implantable glucose sensors 
o  intravascular 
o  subcutaneous 
  minimally invasive sensors 10 
 
o  need loom 
o  with systems of micro dialysis 
o  based on ionophoresis 
  non-invasive sensors 
o  optical 
o  based on spectroscopy 
o  based on light scattering 
In this thesis we will focus on minimally invasive instrumentation and in the particular the 
DexCom Seven Plus
® (Fig. 1.6) used in our experimental protocols. 
 
 
 
Figure 1.4: DexCom Seven Plus
® composed of a small electrochemical sensor placed just 
under the skin, a one-use injector, a transmitter connected to the sensor and monitor which 
receives sensor signal and provides real-time results, [17]. 
 
1.3.2. Subcutaneous Insulin Infusion Pumps 
 
Currently, people with type 1 diabetes have two treatment options for insulin delivery: 
multiple  daily  injections  (MDI)  or  continuous  subcutaneous  insulin  infusion  (CSII)  by 
pump  or  integrated  systems  such  as  pump-continuous  glucose  monitoring  (Sensor 
Augmented Pump, SAP).   
The insulin pump therapy or continuous subcutaneous insulin infusion was introduced over  
 
30 years ago with the aim of improving glycemic control in patients with type 1 diabetes, 
trying  to  mimic  insulin  administration  of  a  healthy  patient.  In  fact,  it  can  reduce  the 
glycemic  variability  within-day  and  between-day  instead  occurs  with  multiple  daily 
injections of insulin [18, 19]. This effect could be related to smaller deposit subcutaneous 
insulin during treatment with the pump (about 1 unit) and low coefficient of variation in 
absorption during the basal rate infusion [20]. The reduction of blood glucose fluctuations 
in patients allows to reduce the levels of glycated hemoglobin without increasing the risk 
of hypoglycemia [18]. 
Insulin  pumps  therefore  represent  the  technical  basis  on  which  the  new  generation  of 
therapeutic tools for the administration of insulin is based.  
Since their appearance in the 80s they have seen a rapid technical evolution that has led 
them to be now able to manage insulin therapy in safety. Nowadays the devices in the 
market offer the possibility to adjust the basal infusion with different speeds depending on 
the time of the day and the same flexibility is guaranteed in the administration of boluses 
with meals.   
In recent years, the technology of the pump system has seen a sharp acceleration with the 
introduction of functionality to support the bolus calculation, on the basis of the amount of 
carbohydrates introduced and integration with systems of self-monitoring and continuous 
monitoring of blood glucose. Most modern systems also contain functions of alarms and 
alerts that allow you to: 
  Inform  in  advance  the  person  on  the  risk  of  occurrence  of  hypoglycemia  and 
hyperglycemia; 
  Operate in a feedback loop in the event of severe hypoglycemia by blocking the 
delivery of insulin. 
 
1.4. Insulin sensitivity indices: state of the art 
 
In  order  to  correctly  evaluate  the  amount  of  insulin  which  should  be  present  in  the 
administered bolus, it would be fundamental to know the value of insulin sensitivity (SI), 
which  corresponds  to  the  ability  of  insulin  to  stimulate  glucose  utilization  and  inhibit 12 
 
glucose production. In fact, knowing the specific insulin sensitivity of the patient and its 
variation during the day will help in determining the optimal insulin treatment. 
Several indices have been published, but the two most important have been favored in the 
past three decades: the clamp insulin sensitivity, SIDF, defined by DeFronzo [21] as the 
ratio  of  glucose  injection  and  insulin  concentration  during  the  hyperinsulinemic-
euglycemic clamp (Fig. 1.8) and the  insulin sensitivity, SIBC, defined by Bergman and 
Cobelli  [22]  which  uses  minimal  model  of  glucose  regulation  during  an  intravenous 
glucose tolerance test (Fig. 1.9). 
The  hyperinsulinemic-euglycemic  glucose  clamp  technique  is  considered  as  the  “gold 
standard” for quantifying insulin sensitivity in vivo because it directly measures the effects 
of insulin to promote glucose utilization under steady state conditions [21]. However, the 
glucose clamp is not easily applied in large scale investigations because i.v. infusion of 
insulin, frequent blood samples over a 3-h period and continuous adjustment of a glucose 
infusion are required for each subject studied. The second method is less invasive than 
clamp  methods,  although  it  involves  frequent  sampling  of  peripheral  plasma  after  an 
intravenous glucose injection (IVGTT). 
 
1.4.1. Hyperinsulinemic-euglycemic clamp 
 
The subject is placed in closed loop and connected to two infusion pumps: a pump infuses 
glucose and a pump infuses insulin. The technique of "glucose clamp" (hyperinsulinemic-
euglycemic clamp) is used to assess insulin sensitivity of the subject, and it represents the 
“gold standard” for the quantification of insulin sensitivity.   
A prime-continuous insulin infusion (Fig. 1.5) is administered to the patient in order to 
raise and maintain insulin concentration at high level steady-state (Iss). In order to keep 
constant  glucose  concentration  at  basal  level,  a  variable  glucose  infusion  is  necessary. 
When the steady-state condition is achieved, the glucose infusion rate (M) equals glucose 
uptake by all the tissues in the body and is therefore a measure of tissue sensitivity to 
exogenous insulin (SI). 
  
 
 
Figure 1.5: Glucose clamp technique, [21]. 
 
1.4.2. Intravenous glucose tolerance test minimal model 
 
This method involves frequent sampling of peripheral plasma after an intravenous glucose 
tolerance  test  (IVGTT):  the  measured  time  course  of  plasma  insulin  concentration  is 
considered as the  “input” and the plasma glucose concentration as the  “output” of the 
system. Model parameters can be estimated from a single IVGTT and provide an explicit, 
quantitative estimate of the insulin sensitivity of the tissues of given subject. 
Glucose  effectiveness  (E)  is  defined  as  the  quantitative  enhancement  of  glucose 
disappearance due to an increase in the plasma glucose concentration 
G
G
E


 

  (1) 
where   ̇  is  the  time  rate  of  change  of  the  plasma  glucose  concentration  (G).  Insulin 
sensitivity is then defined, in steady-state (SS), as the quantitative influence of insulin to 
increase the enhancement of glucose of its own disappearance 
ss I
ss E
SI


   (2) 
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Figure 1.6: IVGTT Glucose Minimal Model, [23]. 
 
  4 1 * p G x p
dt
dG
    
  t I p x p
dt
dx
* * 3 2    
(3) 
where 
 
'
6 4 *I k k x    
3 2 k p    
  5 4 2 3 * k k k p    
0 4 B p   
  0 5 G p   
(4) 
Appling the definitions to the model: 
  4 1 * p G x p G       (5) 
Then  
1 p x E     (6) 
Also at steady state 
ss ss I
p
p
X
2
3     (7) 
So that  
 
1
2
3 p I
p
p
E ss ss      (8) 
Therefore, we define the insulin sensitivity index 
2
3
p
p
SI     (9) 
In this model, the rate of change of glucose is given by the difference between the net 
hepatic glucose balance, B (which may take on positive, production, or negative, uptake, 
values), and the disappearance of glucose into peripheral tissues only (Up). Hepatic glucose 
balance varies according to a relation of the form: 
 G I k k B B
'
6 5 0      (10) 
where B is net glucose balance, and B0 is the net balance expected when plasma glucose 
concentration  is  extrapolated  to  0.  It  is  assumed  that  the  insulin  acts  from  a  remote 
compartment and the disappearance of glucose in peripheral tissues can be expressed as: 
 G I k k Up
'
4 1     (11) 
where “remote” insulin is envisioned to increase the mobility of glucose across the cell 
membrane and this motility potentiates glucose disappearance. 
However,  this  technique  (as  well  as  the  glucose  clamp)  realizes  experimentally  a  “no 
physiological  milieu”  since  neither  the  elevated  insulin-basal  glucose  condition  of  the 
clamp technique nor the rapid glucose and insulin perturbations of an IVGTT reflect the 
conditions  of  daily  living.  Therefore,  it  is  highly  desirable  to  have  a  method  able  to 
quantify insulin sensitivity in a normal life “physiological milieu,” e.g., during a meal. 
 
1.4.3. Other methods 
 
Recently, several methods for determining insulin sensitivity from oral glucose tolerance 
test (OGTT) or meal test (MTT) have been proposed, but the difficulty with oral tests is 
that the  input of the system (rate of glucose appearance)  is unknown. An approach to 
simultaneously identifying parameters describing glucose absorption and insulin sensitivity 
using seven or more blood samples from MTT or OGTT has been developed by Dalla Man 
et al. [24] and was validated against multiple tracer methods in non-diabetic subjects and 16 
 
results  were  well  correlated  with  results  from  hyperinsulinemic  clamps.  However,  this 
method  requires  at  least  seven  blood  samples  to  measure  plasma  glucose  and  insulin 
concentrations  and  the  identification  of  a  model  with  sophisticated  modeling  software. 
Caumo et al. [25] derived an index of insulin sensitivity with an integral approach, but it 
also requires frequent measurements of plasma glucose and insulin concentration after the 
meal; moreover, the method requires that both glucose and insulin concentrations have 
returned to basal values at the end of the experiment. This is a big limitation, since, in type 
1 diabetic subjects, it is not unusual that glucose does not return to pretest glycemic basal 
value due to errors in insulin administration. 
Other more empiric methods for determining insulin sensitivity from OGTT have also been 
proposed. Stumvoll et al. [26] empirically obtained an insulin sensitivity index based on 
glucose and insulin measurements during an OGTT that was correlated with the glucose 
infusion rate during an hyperinsulinemic clamp. Matsuda et al. [27] developed a composite 
insulin sensitivity index based on both fasting and mean values of glucose and insulin and 
showed that this  measure was correlated with results  from an  hyperinsulinemic clamp. 
Hansen et al. [28] empirically determined measures of insulin sensitivity from OGTT that 
were  correlated  with  SI  measured  by  IVGTT.  However,  all  of  them  use  plasma 
measurements. A new empiric approach to evaluate insulin sensitivity has been proposed 
by Breton and Kovatchev [29]. It employs routine self-monitoring blood glucose (SMBG) 
data, collected over a period of 2-6 weeks and it is based on the theory of risk analysis of 
blood  glucose  data,  combined  with  basic  patient  measurements.  This  method  has  the 
advantage to be easy to implement and uses simple data collected in normal daily  life 
conditions, but, due to the long-time collected data, this not takes into account the intraday 
variability of this index which can be present in person’s natural environment.  
To best of our knowledge, until now, there is no method to estimate insulin sensitivity by 
using new technologies such as continuous glucose monitoring and subcutaneous insulin 
infusion devices which provide much more information about patient conditions respect to 
other devices. 
    
 
1.5. Objective 
 
The  aim  of  the  thesis  is  firstly  to  apply  a  new  method  for  the  estimation  of  insulin 
sensitivity (SI), in correspondence of meals, in patients with type 1 diabetes based only on 
CGM sensor and subcutaneous insulin pump. This technique is then applied on both data 
bases to evaluate, in the first one, the sensitivity to CGM errors, and, in the second one, SI 
daily variation.  
Moreover, to improve the estimation of insulin sensitivity with meals close, a function 
which  calculates, at each time, the  amount of carbohydrates absorbed during the  meal 
(Carbohydrates on Board, COB) is developed. At the end, results of insulin sensitivity 
estimation with and without the implementation of this function will be compared to allow 
to evaluate the improvement on insulin sensitivity estimation with meals close. 
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2. Data base and protocols 
 
In this thesis, we used two databases. For the first study, the clinical trials began at the 
University  of  Virginia  (UVA),  followed  by  studies  in  Padova  and  Montpellier.  These 
became  the  first  clinical  trials  to  receive  regulatory  approvals  solely  on  in  silico 
experiments. The second was a multicenter study in which each center followed the same 
protocol.  Both  databases  are  made  up  of  patients  with  type  1  diabetes  who  use 
subcutaneous insulin pump and continuous glucose monitoring systems. 
 
2.1. Data base 1   
 
2.1.1. Subjects 
Data base is made up of 11 patients aged between 21 and 64 years of any racial/ethnic 
group. 
 
Subject  Gender 
[M/F] 
Age 
[years] 
Weight 
[Kg] 
Height 
[Cm] 
6002  M  39  84  180 
6009  M  49  85.5  179 
6012  M  31  69.5  173 
6014  M  39  87.3  180 
6034  F  35  54.5  163 
6035  F  44  60.2  160 
6038  F  30  96.9  165 
6041  F  49  61.9  165 
6042  F  29  66  173 
6043  F  37  66  154 
6044  F  42  68.5  150 
 
Table 2.1: Anthropometric characteristics of data base 1. 
 
For each subject we have: 20 
 
  CGM data of two sensors sampled every 5 minutes (CGM1 e CGM2). 
  SMBG data. 
  Insulin infusion data: basal insulin infusion [U/h] and pre-meal insulin blouses [U]. 
  Glucose loads: meals and hypotreatment [g]. 
Mealtimes are usually kept constant in all subjects:  
  snack at 22:00. 
  breakfast at 08:00. 
  lunch at 14:00. 
The start time data acquisition, for each subject varies between 18:00 and 21:00 as the end 
time data acquisition varies between 13:00 and 15:00 of the next day. 
 
2.1.2. Protocol 
 
a)  Day of admission in the clinic and preparation 
After the first visit (control) occurred a few days before, the subjects may be admitted to 
the clinic for the second visit; subjects can use their own insulin pump containing lispro 
(Humalog) insulin and the physician inserts two DexCom continuous glucose monitors 
(CGMs) sensors into their abdomen. Subjects are very familiar with this equipment as they 
had worn equipment CGM  for about 6-8 weeks during a previous study, which was a 
requirement to participate in this phase. 
Sensors measure the change in glucose levels and they send the information to a beeper-
sized  monitor,  which  stores  the  results.  Subjects  have  to  wear  the  CGMs  until  the 
completion of the second visit. 
After wore the CGM, subjects have to perform all required calibrations with fingerstick 
glucose measurements (approximately two to four calibrations per day). All fingersticks 
are preceded by hand washing with warm water and a dry towel. 
An i.v. catheter is placed to be used for frequent blood sampling during the admission. 
Heat may be applied to the arm with a hospital-supplied heating pad and two IV's are 
placed in forearm or antecubital vein.  
 
  
 
b)  Mixed meal study 
 
A  standardized  meal  containing  0.9  grams  carbohydrate  per  kilogram  body  weight  is 
served for dinner on the evening of admission and insulin is bolused via the patient’s pump 
to  cover  the  meal.  The  subject  is  offered  a  snack  at  10:00  pm  containing  20  grams 
carbohydrates  and  insulin  may  be  bolused  per  the  patient’s  usual  home  regimen.  The 
subject remains fasting except for sugar-free beverages until the following morning. 
Overnight, the subject’s glucose level is monitored via hourly BG measurement with the 
goal of avoiding hypoglycemia prior to the 8AM administration of the mixed meal. For 
glucose  <80  mg/dl,  4  glucose  tablets  will  be  given  (approximately  15-16  grams  of 
carbohydrates).  
In the morning (approximately 8 AM), the subject will undergo a mixed meal and insulin 
challenge as follows: an insulin bolus will be administered and a mixed meal nutrition 
drink will be consumed over 1-5 minutes. The mixed meal nutrition drink is selected for 
that individual to be most likely to raise the glucose levels by 100mg/dl and then return to 
baseline  within  a  four-hour  time  period.  The  nutrition  drink  will  selected  from  the 
following  types  of  product  lines:  Boost  products  (Nestle  Nutrition),  Ensure  products 
(Abbott  Nutrition),  Carnation  Instant  Breakfast  (Nestle  Nutrition)  or  Glucerna  (Abbott 
Nutrition).The pre-meal insulin bolus will be calculated to bring the subject to 100mg/dl 
at 11AM. 
If hypoglycemia of 50-69 mg/dl is not achieved by approximately 12 PM, a second insulin 
bolus will be administered with the goal to induce hypoglycemia of  50-69 mg/dl, and 
again, if hypoglycemia is not occurred by approximately 1:00 PM or is not predicted to 
occur by 1:30 PM, (5-5.5 hours after a mixed meal), the study physician might decide to 
administer an additional insulin bolus at 1:00 PM. 
Glucose is administered to resume euglycemia if blood glucose by YSI will be <60 mg/dl 
at any time during the protocol. The study physician should administer glucose prior to 
blood glucose reaching 60 mg/dl if there was a safety concern such as neuroglycopenic 
symptoms or rapid decline of glucose. Once the subject will reach a hypoglycemic target, 
the subject can have lunch and remain for observation. 
For the mixed meal and insulin sensitivity measures, 8 AM (time 0) will be considered the 
start of the meal and blood samples will be collected at -120, -60, -30, -20, -10, 0, 5, 10, 
15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210 and 240 minutes for insulin, c-peptide, 
and glucose. 22 
 
At approximately 12 PM (240 minutes after the meal), an insulin bolus will be given to 
target  a  blood  glucose  of  50-69  mg/dl  for  measurement  of  hypoglycemic  counter 
regulatory responses. 
 
2.2 Data base 2 
2.2.1. Subjects 
 
The data base available, that represents a subset of a larger one, is relative to the 8 subjects 
of the research center of Montpellier (MTP) and the 7 subjects in the center of Amsterdam 
(AMS) processed each with two closed-loop control algorithms (CAM, IAP), mentioned in 
the next paragraph, and in open-loop (OPEN). 
 
Center  Subject  Algorithm  Age 
[years] 
Weight 
[Kg] 
Height 
[Cm] 
AMS  2  OPEN  8  62  162 
AMS  3  OPEN 
IAP  33  107  207 
AMS  4  OPEN 
CAM  62  93  193 
AMS  6  CAM 
IAP  50  85  185 
AMS  7  IAP 
OPEN  33  74  174 
AMS  8  OPEN 
CAM  28  64  164 
MTP  1  OPEN 
CAM  48  50  150 
MTP  2  OPEN 
CAM  47  78  178 
MTP  4  OPEN 
IAP  45  72  172 
MTP  5 
OPEN 
CAM 
IAP 
52  68  168 
MTP  11  OPEN 
CAM  40  74  174 
MTP  20 
OPEN 
CAM 
IAP 
47  63  163  
 
MTP  39  OPEN 
IAP  49  66  166 
 
Table 2.2: Anthropometric and protocol characteristics of data base 2. 
 
For each subject and for each algorithm used, we have: 
  CGM data sampled every 5 minutes. 
  Plasma glucose concentration. 
  Plasma insulin concentration. 
  Insulin infusion data: basal insulin infusion [U/h] (sampled every minute) and pre-
meal insulin boluses [U]. 
  Glucose loads: meals and hypotreatment [g]. 
 
2.2.2. Protocol 
 
The protocol (called CAT protocol) described here was used for a multicenter study that 
aimed  to  compare  two  existing  control  algorithms  MPC,  namely  the  algorithms  from 
Cambridge (CAM-A) and Padua-Pavia (PP-A), to open loop glycaemic control. 
Each patient will undergo 1 day of closed-loop glycaemic control with the Cambridge 
algorithm (CAM), 1 day of closed-loop control with the Padua-Pavia algorithm (IAP), and 
1 day of open loop control with CSII treatment (control condition), all in randomized order 
to limit potential bias. 
In total was planned to enroll 8 patients for each research center (only 7 in Montpellier), 
male or female, diagnosed with Type 1 Diabetes Mellitus, treated with CSII for a minimum 
of 3 months, aged 18 or above into the study. 
Continuous  Glucose  Measurements  will  be  provided  by  Seven
®Plus  CGM  and  Insulin 
Delivery will be collected from the insulin pump. This device can be linked to a computer 
so that recorded data can be easily exported to a file in xml, csv or text format. The study 
computer where the algorithms are installed will collect all the information in real-time. 
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a)  Day of admission in the clinic 
 
The  day  of  the  study,  the  patient  should  remain  in  the  research  center  for  24  hours. 
Depending on the result of the randomization, this visit correspond either to an open-loop, 
either to a closed-loop with IAP algorithm or to a closed-loop with CAM algorithm. 
  Subject arrives around 17:30 hours to the Centre. 
  Two research clocks pre-set to the official time are placed in the room. The insulin 
pump, continuous glucose monitor, and all study procedures are referenced to the 
official time. 
  Plasma glucose is measured using the YSI measurement device, which is calibrated 
and optimized until a 10 mmol/L glucose standard reads 9.8-10.2 mmol/L. 
  The CGM device is calibrated with YSI glucose measurements. 
  By  18:00  hours,  two  20  Gauge  indwelling  catheters  are  placed  in  different 
antecubital  veins  for  sampling  of  plasma  glucose  and  insulin  and  infusion  of 
glucose if required. 
  Blood is sampled every 30 minutes from 19:00 the first day to 18:00 the second day 
except during the following events: 
o  Night  time:  between  23:00  and  07:00  hours  the  sampling  schedule  is 
reduced to once every 60 minutes. 
o  Meals: blood is sampled every 15 minute from the start of a meal until 2 
hours afterwards. 
o  Exercise:  blood  is  sampled  every  15  minute  during  exercise  and  until  2 
hours after the start of the exercise. 
  The study pump will be initiated and a new catheter inserted by 18:00 and the 
subjects own insulin pump are stopped. 
  Initialization of the closed-loop system begins at 19:00 hours. 
  Initialization of the controller occurs prior to closed loop initiation and includes 
configuration of nominal basal insulin pattern for the visit. 
  Patient receives dinner at 19:00. This standardized meal consists of 80 grams of 
carbohydrates which should be fully ingested within 20 minutes. All meals will be 
identical on different study days. If the visit corresponds to a closed loop, the meal 
insulin bolus is calculated by the algorithm. Otherwise, patient calculates his need 
of insulin.  
 
  Patients are allowed to sleep from 23:00 to 07:00 hours the following day. 
  Patients receive breakfast at 08:00 hours with a carbohydrate content of 50 grams 
which should be fully ingested within 20 minutes.  
  Patients  receive  lunch  at  12:00  hours  with  a  carbohydrate  content of  60  grams 
which should be fully ingested within 20 minute. 
  Exercise follows at 15:00 hours. 
  Automated closed-loop control ends at 18:00 and then patient is allowed to leave 
the Center when blood glucose is stable (>4.4 mmol/L). 
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3. Methods 
 
3.1.  A  new  index  of  insulin  sensitivity  from  minimally 
invasive technologies 
 
The estimation of this new index of insulin sensitivity (SICGM&PUMP) [30] employs a simple 
integral approach with suitable approximations to simplify integral calculations, without 
the  need  to  solve  any  differential  equation.  In  particular  the  following  ingredients  are 
required: 
  The area under the curve (AUC) of above basal CGM data during the meal. 
  The area under the curve of subcutaneous insulin infusion (Inf) data during the 
meal    and,  possibly,  an  estimation  of  the  delayed  effect  of  insulin  boluses 
administered before the meal by using an Insulin on Board algorithm (IOB) [31]. 
  The amount of glucose ingested during the meal (D). 
  Patient  specific  parameters  such  as  body  weight  (BW),  age  and  height  for  the 
estimation, by using population models [32], of plasma insulin clearance (CL). 
  Population values of glucose kinetics parameters [33] such as glucose effectiveness 
at  zero  insulin  (GEZI),  fraction  of  the  ingested  glucose  which  appears  in  the 
systemic circulation (f), and volume of glucose distribution (VG). 
The  method  used  to  calculate  an  estimation  of  insulin  sensitivity  is  made  up  of  four 
components (Fig. 3.1): 
a)  Glucose module: it considers continuous glucose monitoring data [mg/dl], from the 
start of the meal till six hours later (time at which the glucose absorption of the 
meal is assumed to be ended) and calculates the area under the curve (AUC) with 
the trapezoidal rule. If available, at least two SMBG references could be used for 
the calibration, with such an algorithm as [34], of CGM signal. 
b)  Insulin module: it considers the subcutaneous insulin infusion data [mU/min] from 
three hours before the start of the meal, to take into account, by using an Insulin on 
Board  algorithm  (IOB)  [27],  the  delayed  effect  of  insulin  correction  boluses 28 
 
administered before the pre-meal bolus, till six hours later and calculates area under 
the curve. 
c)  Patient module: uses the specific data of the patient mentioned above and the dose 
of the meal. 
d)  SI calculator: is the core of the method and it employs a simple integral approach, 
without  the  need  to  solve  any  differential  equation,  to  evaluate  the  insulin 
sensitivity by using simple algebra formula. 
  
 
Figure 3.1: Schematic diagram showing main modules used to calculate the SICGM&PUMP, 
[30]. 
 
3.2. Estimation of carbohydrates on board: COB 
 
This function is based on the model of gastro-intestinal tract (Fig. 3.2) which assumes two 
compartments for the stomach (one for the liquid and one for the solid phase) a gastric 
empting rate (kempt) dependent on the total amount of glucose in the stomach (qsto), a single 
compartment for the intestine (qgut) and a constant rate of intestinal absorption (kabs). Many 
authors agree [35-41] that the gastric emptying of liquids occurs exponentially and depends 
on the size of the meal, its energy density and the amount of nutrient in the stomach. On  
 
the other hand, with increasing nutrient and caloric content of the liquid phase of the meal, 
there is a deceleration from the exponential model and closer approximation to linearity. 
Starting from the knowledge of the amount of carbs ingested at time m t , the COB function 
is  able  to  evaluate,  at  each  time m t t  , the  percentage  of  carbs  not  yet  absorbed.  For 
360   m t t min, it is assumed the percentage of carbs not yet absorbed is lower than 10% 
[42]. 
 
 
Figure 3.2: Model of gastro-intestinal tract, [42]. 
 
The model showed above is described by the following equations: 
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With parameters a and c constrained by imposing that  max k kempt   for both  D qsto   and 
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We can calculate the value of f by the ratio of AUCs between the rate of appearance of 
glucose after the meal, assuming that at the end of the meal the total fraction of the meal 
which appears into plasma is equal to 9 . 0   f . 
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Thus we can obtain the value of Carbs On Board, COB: 
    t f f t COB      (17) 
 
3.3. Incorporation of COB in insulin sensitivity estimates 
 
This function can be used to estimate insulin sensitivity from CGM and insulin pump data 
[30] when meals are close each other, i.e. less than 360 minutes, and therefore the previous 
meal has not been fully absorbed. 
When two meals are  close one to each other, we can  split  the carbs content  into two 
components: 
1.  First component: by using the function f, we can obtain the amount of the meal 
absorbed up to the desired instant by multiplying the meal dose for the value of the 
function at that time. 
2.  Second component: by using the function COB, we can obtain the amount of the 
meal which has not been yet absorbed by multiplying the previous meal dose for 
the value of the function at that time. This value can then be added to the next meal 
dose to obtain the total carbs amount which will be absorbed by the start of the 
second meal.  
 
This procedure can be repeated for the following meals.Moreover, also a hypotreatment is 
administered close to a meal could affect the estimation of the insulin sensitivity because 
the relative increase in glucose concentration due to hypotreatment, which could reduce the 
estimation of insulin sensitivity, in this case it is compensated by an opportune addition of 
carbs to the meal dose.   
It should be considered, therefore, that the development of the functions f and COB cannot 
be  identical  for  each  type  of  meal,  but  as  we  shall  see  later,  varies  depending  on  the 
composition and the amount of the meal assumed. 
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4. Results 
 
4.1. COB from simulated data 
 
In this first phase COB and f functions are extracted in a simulated environment thank to 
the  availability  of  a  type  1  diabetes  mellitus  simulation  model  of  the  glucose-insulin 
system  during  a  meal  accepted  by  the  Food  and  Drugs  Administration  (FDA)  as  a 
substitute to animal trials for certain insulin treatments [43]. T1DM simulator is equipped 
with a cohort of in silico subjects which permit to simulate inter-individual variability of 
key metabolic parameters in the T1DM population. In silico subjects are generated from a 
distribution of the parameters which characterize the physiological model of the glucose-
insulin system described in [42]. Parameters estimates are obtained by fitting the model to 
individuals data collected in clinical trial. 
To extract COB and f functions, 100 in silico subjects were generated using the distribution 
of the parameters variations of the entire glucose-insulin model.    
Starting from the gastro-intestinal model [42] and the parameters extracted from the 100 in 
silico  subjects,  COB  and  f  functions  for  both  hypotreatment  and  standard  meal  were 
defined. 
For each subject, we calculated the glucose rate of appearance in plasma (Ra) using the 
relation  shown  in  Section  3.2  both  for  hypotreatment  and  meal.  The  glucose  rate  of 
appearance in plasma after a hypotreatment (D = 20 g), due to its known rapid absorption, 
is obtained after linearization of the model of the gastro-intestinal tract (Fig. 4.1); while for 
a standard meal (D = 50 g), which is known to be slower than the previous, is obtained by 
the standard gastro-intestinal model (Fig. 4.2).   
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Figure 4.1: Median  IQR range of glucose rate of appearance (Ra) after a hypotreatment 
(D = 20 g) of the 100 in silico subjects. 
 
 
Figure 4.2: Median  IQR range of glucose rate of appearance (Ra) after a standard meal 
(D = 50 g) of the 100 in silico subjects. 
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Then, as previously defined, the functions f(t) and COB(t) are obtained, for each time, by 
the area under the curve of glucose rate of appearance Ra(t) and hypotreatment/meal dose. 
Below  are  shown  the  median  COB,  obtained  by  the  100  in  silico  subjects,  for  a 
hypotreatment (Fig. 4.3) and for a standard meal (Fig. 4.4), respectively. 
 
 
Figure 4.3: Median  IQR range of COB function of the 100 in silico subjects after a 
hypotreatment. 
 
 
Figure 4.4: Median  IQR range of COB function of the 100 in silico subjects after a 
standard meal. 
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As known from literature the hypotreatment administered to the patient is absorbed more 
quickly than a standard meal. 
 
4.2. COB from real data 
 
Parameters of the gastro-intestinal tract, extracted with an identification study using the 
Bayesian  estimation  technique  MAP  (Maximum  A  Posteriori),  where  the  a  priori 
information of the glucose-insulin model [44] is available in [45], from plasma glucose and 
insulin concentration are available. 
For every single subject and meal, because parameters are thought to be dependent on meal 
composition, the parameters of the gastro-intestinal tract (kabs, kmax and kmin, while b and d 
are maintained constant for all meals) have been identified, obtaining a total of 258 groups. 
Among  these  groups,  only  parameters  which  presented  a  satisfactory  fit  of  the  model 
compared to the data are selected. 
In the same way for simulated data, functions f and COB are obtained for every different 
meal (breakfast = 50 g, lunch = 60 g and dinner = 80 g).   
Below are shown the average parameters (Table 4.1 and Fig. 4.5) and distributions (Fig. 
4.6-7-8)  of  meal-varying  parameters  of  the  gastro-intestinal  tract  identified  from  all 
subjects. 
 
Mean(sd)  Breakfast  Lunch  Dinner 
Kabs  0.1853(0.0746)  0.1944(0.2071)  0.2117(0.1787) 
Kmax  0.0638(0.2906)  0.0356(0.0251)  0.0824(0.0186) 
Kmin  0.0175(0.0124)  0.0087(0.0069)  0.0095(0.0057) 
 
Table 4.1: Average meal-varying parameters identified for all subjects with standard 
deviation subdivided by meal type. 
  
 
 
Figure 4.5: Graphic display of average parameters with their standard error. 
 
 
Figure 4.6: Distribution of the parameter kabs for breakfast (red), lunch (green) and dinner 
(blue). 
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Figure 4.7: Distribution of the parameter kmax for breakfast (red), lunch (green) and dinner 
(blue). 
 
 
Figure 4.8: Distribution of the parameter kmin for breakfast (red), lunch (green) and dinner 
(blue). 
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As can be seen from the figures shown above, the distribution of the parameters is similar 
as regards lunch and dinner, while breakfast is different from the previous especially in the 
case of kmin and kmax. 
To  demonstrate  it,  also  from  a  statistical  point  of  view,  a  two-tailed  t-test  for  each 
combination of the same parameters for different meals (Breakfast vs Lunch, Breakfast vs 
Dinner and Lunch vs Dinner) was performed in Table 4.2. 
 
 
Breakfast 
vs 
Lunch 
Breakfast 
vs 
Dinner 
Lunch 
vs 
Dinner 
Kabs  0.819  0.4736  0.5702 
Kmax  0.0018  0.0002  0.3564 
Kmin  6 10 7 . 4
   
8 10 97 . 7
    0.4606 
 
Table 4.2: P-value of two-tailed t-test for each combination of the same parameters for the 
different meals. 
 
As we can see in Table 4.2, kmax and kmin are different for breakfast respect to lunch and 
dinner while parameter kabs does not change. This feature, due to the different composition 
of the meal (percentage of fats, proteins and carbohydrates), is thus presented also on the 
COB functions extracted (shown below) and it will allow us, in the implementation phase, 
to distinguish the COB function depending on meal composition (Fig. 4.9-10-11). 
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Figure 4.9: Median  IQR range of COB function of the real subjects during breakfast. 
 
 
Figure 4.10: Median  IQR range of COB function of the real subjects during lunch. 
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Figure 4.11: Median  IQR range of COB function of the real subjects during dinner. 
 
As expected, the difference can be seen especially between breakfast respect to lunch and 
dinner, which are similar each other, this meal is in fact absorbed about 100 minutes earlier 
than lunch or dinner while the latters have a remarkably similar pattern. 
 
4.3. Insulin sensitivity 
 
Firstly for the estimation of insulin sensitivity, it was necessary to extract the time window 
of analysis for the calculation of the area under the curve of the CGM signal and the area 
under the curve of basal insulin infusion with meal boluses. Moreover, for some subjects, 
was also necessary to apply linear interpolation to fill the areas in which CGM values were 
missing due to an incorrect sampling of the sensor. 
In the time windows analyzed only one meal at a time is analyzed and they contain data 
(CGM and insulin infusion) of at least 3 hours prior to the meal, so as to extract the insulin 
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on board (IOB), and data about 6 hours after administration of the meal to allow the CGM 
signal to return to steady state (Fig. 4.12). 
 
 
Figure 4.12: Up: two CGM signals (blue and black line) with the time window analyzed 
for SI estimation (red); middle: meals; bottom: basal insulin infusion and pre-meal boluses 
(blue and black line, respectively) with the pre-meal time window for IOB calculation 
(yellow). 
 
In the Section 4.3 we estimate insulin sensitivity with the standard formulation, i.e. without 
the introduction of the COB function, to analyze: 
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  Data base 1: by protocol there are two CGM sensors, so this part is dedicated to the 
analysis of the sensitivity of the formula to the error of the sensor. 
  Database 2: by protocol there are three different meals (dinner, breakfast and lunch) 
so  this  part  is  dedicated  to  the  extraction  of  SI  during  a  day  in  normal  living 
conditions and to assess whether there are patterns of SI. 
 
4.3.1. Data base 1 
 
In this data base we have two CGM signals for each patient, so we estimate two values of 
insulin sensitivity, two for each patient, and then we calculate the average SI (SIcgmM) for 
each patient (Tab. 4.3). 
Subject  SIcgm1  SIcgm2  SIcgmM 
6002    8.73   
6009  16.23  10.81  13.32 
6012  14.59  2.04  6.4 
6014  20.9  16.58  18.87 
6034  48.49  52.65  50.51 
6035  20.7  24.95  23.28 
6038  9.44  16.7  12.27 
6041  21.82  25.99  25.33 
6042  6.06  9.03  7.42 
6043  17.13  27.44  21.58 
6044  12.12  8.8  10.28 
 
Table 4.3: SI estimates, two for each subjects, and the average SI. 
 
SI estimates are similar for each subjects, depending on CGM signals, except for 3 of them 
(marked in red) where the percentage relative distance (d) from the respective average SI is 
in average of 50%. 
    
|               |   |               |
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The absolute difference between SI estimates |(SIcgm1-SIcgm2)| is significantly correlated ( 
= 0.8236, p = 0.003) to the difference between the areas under the curve (AUC) of the two 
CGM signals |(AUCcgm1-AUCcgm2)|, where, in this case, the calculated area under the basal 
glycemic value is added with positive sign. 
Instead, the correlation between the SI index and the respective AUC is: RHO = -0.66 with 
PVAL = 0.0016. 
In conclusion, the result of correlation emphasizes the importance of a good calibration of 
the sensor during the study to obtain an SI estimation as accurate as possible. 
 
4.3.2. Data base 2 
 
In this data base we have three different meals, thus we estimate insulin sensitivity for each 
meal. In the table below (Table 4.4) is shown the mean SI estimates for each meal. 
 
  Dinner  Breakfast  Lunch 
Mean  45.53  24.33  35.17 
Median  42.44  17.80  33.02 
SD  35.535  22.26622  25.011 
SE  9.1053  4.86544  7.0344 
 
Table 4.4: Mean SI estimates, for each meal, obtained by all the subjects of data base 2. 
 
It  may  happen  that  a  few  SI  estimates  result  negative:  these  values  are  associated  to 
subjects who did not return to pretest glycemic basal value, but continued to rise even long 
time after the meal. This is probably caused by too small pre-meal insulin bolus which is 
not able to compensate the total amount of glucose entering the system after the meal.  
 
 
Figure 4.13: Mean SI for each meal with their standard error. 
 
As we can see in Fig. 4.13, the physiological change in insulin sensitivity during different 
times of the day is confirmed by the estimates obtained: during dinner and lunch mean SI 
results higher than breakfast, where, before awakening, greater quantities hormones that 
cause insulin resistance such as cortisol and growth hormone are produced [46, 47]. 
 
4.4. Insulin sensitivity with COB 
 
In this Section, we carry out the same analysis of Section 4.3, but with the incorporation of 
COB function, to take into account the contribution of meals close, into the estimation of 
insulin sensitivity.  In Fig. 4.14 is shown a schematic diagram of what has been described 
in Section 3.3 for calculation of the total dose at the instant of the SI estimation. 
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Figure 4.14: Graphical view of how COB and f functions work. The term B is the dose that 
corresponds to breakfast, L lunch, and H to a hypothetical hypotreatment. The temporal 
distances d, d1, d2, d3 are used to calculate the corresponding values of COB and f. 
 
For the estimation of insulin sensitivity  in correspondence of a meal  it is necessary to 
know: 
  Dose of the meal analyzed. 
  Dose  of  meals,  or  hypotreatments,  administered  before  the  start  of  the  time 
window analyzed, because they could not have been completely absorbed up to the 
start of the meal. 
  Dose of meals administered before the end of the time window analyzed, because 
they could be partially absorbed. 
Thus  COB  and  f  functions  are  used  for  this  purpose,  i.e.  to  account  for  meals  not 
completely absorbed before or after the start of the meal during the time window analyzed. 
  
 
4.4.1. Data base 1 
 
In this section has been implemented the functions f and COB for the estimation of insulin 
sensitivity.  In  this  case  the  dose  used  will  be  reduced  by  the  function  f  because  the 
calculation of SI is stopped before 360 minutes (time which is assumed for the complete 
absorption of the meal).  
 
Subject  SIcgm1  SIcgm2  SIcgmM 
6009  23.03  17.08  19.98 
6012  14.57  2.04  6.39 
6014  20.87  16.56  18.84 
6034  33.81  36.41  35.07 
6035  24.26  30.67  27.25 
6038  9.29  16.68  12.16 
6041  21.66  25.96  25.30 
6042  6.31  11.54  8.75 
6043  11.59  21.46  15.26 
6044  12.04  8.74  10.21 
 
Table 4.5: SI estimates, two for each subjects, and the average SI with the function COB 
implemented. 
 
The absolute difference between SI estimates | (SIcgm1-SIcgm2)| is correlated ( = 0.8415, p 
= 0.002) with the difference between the areas under the curve (AUC) of the two CGM 
signals  |(AUCcgm1-AUCcgm2)|,  where,  in  this  case,  the  calculated  area  under  the  basal 
glycemic value is added with positive sign. 
 
4.4.2. Data base 2 
 
The use of the COB and f functions influence the estimation of the insulin sensitivity of 
each meal:  
  Dinner: if there is a hypotreatment in the time window of analysis. 48 
 
  Breakfast: in general, the dose is not completely absorbed because of the proximity 
to  the  lunch  (separated  by  less  than  360  minutes)  and  hypotreatment  could  be 
administered.  
  Lunch: in general the dose of breakfast is not completely absorbed before the start 
of the lunch, thus we have to take into account its contribution to the meal dose, 
and any hypotreatment administered. Moreover, the dose may be reduced if the 
time window after the meal is less than 360 minutes. 
 
  Dinner  Breakfast  Lunch 
Mean  47.33  25.23  41.79 
Median  42.71  17.41  37.65 
SD  35.31  23.71  24.36 
SE  7.06  4.74  4.87 
 
Table 4.6: Mean SI estimates, for each meal, obtained by all the subjects of data base 2. 
 
 
Figure 4.15: Average and standard error of the SI for each meal using the COB. 
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4.5. Comparison 
 
The comparison between the estimates obtained with and without the implementation of 
the function COB emphasizes how the proximity of two meals may affect the calculation 
of insulin sensitivity and the importance of assessing the amount of carbohydrates not yet 
absorbed. 
In addition a glucose load administered between meals should be taken into account during 
the estimation of insulin sensitivity, in fact, it implies a glycemic excursion and thus it 
modifies its area under the curve which is used for the calculation of the SI. 
In Fig. 4.16 is shown the comparison between the mean SI estimates obtained in data base 
1 with and without the COB function. 
 
 
Figure 4.16: Comparison between mean SI estimates with and without COB for data base 
1. 
As we can see the mean SI estimates for breakfast with the COB function are slightly 
lower  respect  to  the  ones  without  the  function,  thus  confirming  the  hypothesis.  The  f 
function lowers the dose administered due to time window is less than 360 minutes, even if 
the effect on mean SI estimates is small due to the fast absorption of meal dose. 
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In Fig. 4.17 is shown the comparison between the mean SI estimates obtained in data base 
2 with and without COB function for dinner. 
 
 
Figure 4.17: Comparison of mean SI estimates for dinner with and without COB. 
 
As hypothesized, SI estimates with and without the COB function is, on average, very 
similar: in fact there is no information about previous meals. The slight increase of SI with 
COB is probably due to the presence of hypotreatments which are not accounted without 
the COB function.  
In Fig. 4.18 is shown the comparison between the mean SI estimates obtained in data base 
2 with and without COB function for breakfast. 
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Figure 4.18: Comparison of mean SI estimates for breakfast with and without COB. 
 
Fig. 4.18 shows an increase of SI with the COB function. This initially appears rather 
unexpected, because a decrease of insulin sensitivity due to the presence of the next close 
meal, which does not allow the complete absorption of the dose, is expected. The slight 
increase of SI with COB is probably due to the compensation on the total dose, in some 
subjects, between the administration of hypotreatments, which are accounted to be rapidly 
absorbed by the COB function, and the reduction of the breakfast meal dose due to the 
presence of the next meal close.  
In Fig. 4.19 is shown the comparison between the mean SI estimates obtained in data base 
2 with and without COB function for lunch. 
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Figure 4.19: Comparison of mean SI estimates for breakfast with and without COB. 
 
In  this  case  there  is  a  pronounced  increase  of  SI  estimates  with  the  COB  function, 
compared to the previous cases, probably due to both the portion of breakfast meal dose 
which is not yet absorbed and the presence of hypotreatments, which are not taken into 
account without the COB function. 
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4.6 Assessment of insulin sensitivity daily variability 
 
In this section, the Fig. 4.19 is shown to demonstrate insulin sensitivity daily-variability 
that, even after using COB function, it maintained a certain pattern although the average 
values vary. 
 
 
Figure 4.19: Mean SI with and without COB for each meal with their standard error. 
It is evident that the average value of insulin sensitivity for breakfast is significantly lower 
than the SI  for  lunch and dinner and this  is concordant with what we know  from the 
literature. 
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5. Conclusions 
 
The purpose of this work is to estimate an index of insulin sensitivity in patients with type 
1 diabetes through a new method which exploits minimally-invasive technologies such as 
subcutaneous glucose (continuous glucose monitoring, CGM) sensing and insulin delivery 
in  everyday  life  condition.  This  method  allows  the  estimation  of  an  index  of  insulin 
sensitivity, in correspondence of meals, by integration of CGM and insulin infusion data 
and using subject-specific parameters approximated using field-measurable characteristics 
of the patient. From data base 1, thanks to the presence of two CGM signals, a study of the 
sensitivity of the formula to the error of the sensor is performed. It was obtain that the 
sensitivity of the SI estimates is strongly correlated ( = 0.8236 and p = 0.003) with the 
area under the curve of the CGM sensor, as one  might expect, and this allowed us to 
confirm  how  important  is  a  good  calibration  of  the  CGM  sensor to  correctly  evaluate 
patient  condition.  From  data  base  2  an  analysis  of  SI  daily  variability,  thanks  to  the 
availability of three contiguous meals (dinner, breakfast and lunch), is performed. These 
preliminary results  showed a pattern of SI during the day,  in  fact, on average,  insulin 
sensitivity at breakfast is lower than lunch and dinner, as known from the literature. 
However, the method used for the estimation of insulin sensitivity, to be properly applied, 
assumes the distance between contiguous meals to be at least six hours because, at that 
time, the carbs amount ingested should be completely absorbed. In fact, in presence of 
meals  close,  the  dose  of  a  meal  that  is  not  completely  absorbed  should  contribute  to 
glucose  excursions  of  the  next  meal,  thus  it  is  necessary  to  take  into  account  of  this 
contribution.To overcome  this  limitation,  a  function  which  evaluates the  percentage  of 
carbs  not yet absorbed by the gastro-intestinal tract is developed. This  function, called 
Carbs  on  Board  (COB),  is  firstly  estimated  in  a  simulated  environment  thanks  to  the 
availability of 100  in silico subjects generated using the distribution of the parameters 
variation of the type 1 diabetes mellitus simulation model of the glucose-insulin system 
during a meal accepted by the Food and Drugs Administration (FDA) [48]. This function is 
then  estimated  using  real  data  thanks  to  the  availability  of  parameters  of  the  gastro-
intestinal tract obtained by an identification study on different meals from plasma glucose 
and  insulin  concentration  [45].  Through  a  statistical  analysis  conducted  on  parameter 56 
 
estimates,  it  was  observed  that  some  parameters  differ  among  meals,  especially  for 
breakfast  (p  <<  0.05)  respect to  lunch  and  dinner,  which  is  in  agreement  with  meals 
composition,  i.e.  lunch  and  dinner  are  very  similar  respect to  breakfast.  By  using  this 
information,  in  order  to  make  more  reliable  the  estimation  of  carbs  not  yet  absorbed 
between meals close, we developed different COB functions depending on the type of meal 
administered. Therefore the COB function is used to improve the estimation of insulin 
sensitivity, described before, also in condition of meals close. The comparison of results 
showed, also in this case, the previously observed pattern of SI during the day,  i.e., on 
average, insulin sensitivity at breakfast is lower than lunch and dinner, even though mean 
values of SI are different from the previous one thanks to the contribution of meals close in 
the insulin calculation process. 
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